crx-526 and Inflammatory-Bowel-Diseases

crx-526 has been researched along with Inflammatory-Bowel-Diseases* in 1 studies

Other Studies

1 other study(ies) available for crx-526 and Inflammatory-Bowel-Diseases

ArticleYear
A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease.
    Journal of immunology (Baltimore, Md. : 1950), 2005, May-15, Volume: 174, Issue:10

    Current evidence indicates that the chronic inflammation observed in the intestines of patients with inflammatory bowel disease is due to an aberrant immune response to enteric flora. We have developed a lipid A-mimetic, CRX-526, which has antagonistic activity for TLR4 and can block the interaction of LPS with the immune system. CRX-526 can prevent the expression of proinflammatory genes stimulated by LPS in vitro. This antagonist activity of CRX-526 is directly related to its structure, particularly secondary fatty acyl chain length. In vivo, CRX-526 treatment blocks the ability of LPS to induce TNF-alpha release. Importantly, treatment with CRX-526 inhibits the development of moderate-to-severe disease in two mouse models of colonic inflammation: the dextran sodium sulfate model and multidrug resistance gene 1a-deficient mice. By blocking the interaction between enteric bacteria and the innate immune system, CRX-526 may be an effective therapeutic molecule for inflammatory bowel disease.

    Topics: Adjuvants, Immunologic; Animals; Anti-Inflammatory Agents, Non-Steroidal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caproates; Cells, Cultured; Colitis; Dextran Sulfate; Disease Models, Animal; Female; Glucosamine; HeLa Cells; Humans; Inflammatory Bowel Diseases; Lipid A; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Knockout; Monocytes; Receptors, Immunologic; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha

2005